Colloca, L. et al. Neuropathic pain. Nat. Rev. Dis. Prim. 3, 17002 (2017).
Alsaloum, M., Higerd, G. P., Effraim, P. R. & Waxman, S. G. Status of peripheral sodium channel blockers for non-addictive pain treatment. Nat. Rev. Neurol. 16, 689–705 (2020).
Article CAS PubMed Google Scholar
Finnerup, N. B. et al. Neuropathic pain clinical trials: factors associated with decreases in estimated drug efficacy. Pain 159, 2339–2346 (2018).
Article CAS PubMed PubMed Central Google Scholar
Mbowe, O. B., Gewandter, J. S., Turk, D. C., Dworkin, R. H. & McDermott, M. P. Are there really only 2 kinds of people in the world? Evaluating the distribution of change from baseline in pain clinical trials. Pain 161, 195–201 (2020).
Article PubMed PubMed Central Google Scholar
Attal, N., Bouhassira, D. & Baron, R. Diagnosis and assessment of neuropathic pain through questionnaires. Lancet Neurol. 17, 456–466 (2018).
Pascal, M. M. V. et al. DOLORisk: study protocol for a multi-centre observational study to understand the risk factors and determinants of neuropathic pain. Wellcome Open Res. 3, 63 (2018).
Corder, G. et al. An amygdalar neural ensemble that encodes the unpleasantness of pain. Science 363, 276–281 (2019).
Article CAS PubMed Google Scholar
Daou, I. et al. Remote optogenetic activation and sensitization of pain pathways in freely moving mice. J. Neurosci. 33, 18631–18640 (2013).
Article CAS PubMed PubMed Central Google Scholar
Soliman, N., Rice, A. S. C. & Vollert, J. A practical guide to preclinical systematic review and meta-analysis. Pain 161, 1949–1954 (2020).
Rice, A. S. C. et al. Transparency in the reporting of in vivo pre-clinical pain research: the relevance and implications of the ARRIVE (animal research: reporting in vivo experiments) guidelines. Scand. J. Pain 4, 58–62 (2013).
Knopp, K. L. et al. Experimental design and reporting standards for improving the internal validity of pre-clinical studies in the field of pain: consensus of the IMI-Europain consortium. Scand. J. Pain 7, 58–70 (2015).
Article CAS PubMed Google Scholar
Decosterd, I. & Woolf, C. J. Spared nerve injury: an animal model of persistent peripheral neuropathic pain. Pain 87, 149–158 (2000).
Dickenson, A. H. & Patel, R. Translational issues in precision medicine in neuropathic pain. Can. J. Pain 4, 30–38 (2020).
Article PubMed PubMed Central Google Scholar
Field, M. J. et al. Identification of the α2-δ-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin. Proc. Natl Acad. Sci. USA 103, 17537–17542 (2006).
Article CAS PubMed PubMed Central Google Scholar
Patel, R. & Dickenson, A. H. Neuronal hyperexcitability in the ventral posterior thalamus of neuropathic rats: modality selective effects of pregabalin. J. Neurophysiol. 116, 159–170 (2016).
Article CAS PubMed PubMed Central Google Scholar
Demant, D. T. et al. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double-blind, placebo-controlled phenotype-stratified study. Pain 155, 2263–2273 (2014).
Article CAS PubMed Google Scholar
Patel, R., Kucharczyk, M., Montagut-Bordas, C., Lockwood, S. & Dickenson, A. H. Neuropathy following spinal nerve injury shares features with the irritable nociceptor phenotype: a back-translational study of oxcarbazepine. Eur. J. Pain 23, 183–197 (2019).
Article CAS PubMed Google Scholar
McDonnell, A. et al. Efficacy of the Nav1.7 blocker PF-05089771 in a randomised, placebo-controlled, double-blind clinical study in subjects with painful diabetic peripheral neuropathy. Pain 159, 1465–1476 (2018).
Article CAS PubMed Google Scholar
Cao, L. et al. Pharmacological reversal of a pain phenotype in iPSC-derived sensory neurons and patients with inherited erythromelalgia. Sci. Transl. Med. 8, 335ra56 (2016).
Goodwin, G., McMurray, S., Stevens, E. B., Denk, F. & McMahon, S. B. Examination of the contribution of Nav1.7 to axonal propagation in nociceptors. Pain 163, e869–e881 (2022).
Article CAS PubMed Google Scholar
Kraus, R. L. et al. Nav1.7 target modulation and efficacy can be measured in nonhuman primate assays. Sci. Transl. Med. 13, eaay1050 (2021).
Article CAS PubMed Google Scholar
Gewandter, J. S. et al. Predicting treatment response with sensory phenotyping in post-traumatic neuropathic pain. Pain. Med. 23, 1726–1732 (2022).
Fisher, A. S., Lanigan, M. T., Upton, N. & Lione, L. A. Preclinical neuropathic pain assessment; the importance of translatability and bidirectional research. Front. Pharmacol. 11, 614990 (2020).
Article CAS PubMed Google Scholar
Hunt, J., Knazovicky, D., Lascelles, B. D. X. & Murrell, J. Quantitative sensory testing in dogs with painful disease: a window to pain mechanisms? Vet. J. 243, 33–41 (2019).
Edvinsson, L. CGRP and migraine: from bench to bedside. Rev. Neurol. 177, 785–790 (2021).
Article CAS PubMed Google Scholar
Wise, B. L., Seidel, M. F. & Lane, N. E. The evolution of nerve growth factor inhibition in clinical medicine. Nat. Rev. Rheumatol. 17, 34–46 (2021).
Claussnitzer, M. et al. A brief history of human disease genetics. Nature 577, 179–189 (2020).
Article CAS PubMed PubMed Central Google Scholar
Calvo, M. et al. The genetics of neuropathic pain from model organisms to clinical application. Neuron 104, 637–653 (2019).
Article CAS PubMed PubMed Central Google Scholar
Zorina-Lichtenwalter, K., Parisien, M. & Diatchenko, L. Genetic studies of human neuropathic pain conditions: a review. Pain 159, 583–594 (2018).
Article CAS PubMed Google Scholar
Sun, B. B. et al. Genetic associations of protein-coding variants in human disease. Nature 603, 95–102 (2022).
Article CAS PubMed PubMed Central Google Scholar
Burand, A. J. & Stucky, C. L. Fabry disease pain: patient and preclinical parallels. Pain 162, 1305–1321 (2021).
Article CAS PubMed Google Scholar
Asiri, M. M. H., Engelsman, S., Eijkelkamp, N. & Höppener, J. W. M. Amyloid proteins and peripheral neuropathy. Cells 9, E1553 (2020).
Adams, D., Koike, H., Slama, M. & Coelho, T. Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease. Nat. Rev. Neurol. 15, 387–404 (2019).
Article CAS PubMed Google Scholar
Houlden, H. et al. Clinical, pathological and genetic characterization of hereditary sensory and autonomic neuropathy type 1 (HSAN I). Brain 129, 411–425 (2006).
Kok, K. et al. Fabry disease: molecular basis, pathophysiology, diagnostics and potential therapeutic directions. Biomolecules 11, 271 (2021).
Article CAS PubMed PubMed Central Google Scholar
Sachau, J., Kersebaum, D., Baron, R. & Dickenson, A. H. Unusual pain disorders–what can be learned from them? J. Pain Res. 13, 3539–3554 (2020).
Fridman, V. et al. Randomized trial of l-serine in patients with hereditary sensory and autonomic neuropathy type 1. Neurology 92, e359–e370 (2019).
Article CAS PubMed PubMed Central Google Scholar
Bennett, D. L., Clark, A. J., Huang, J., Waxman, S. G. & Dib-Hajj, S. D. The role of voltage-gated sodium channels in pain signaling. Physiol. Rev. 99, 1079–1151 (2019).
留言 (0)